Xenon Pharmaceuticals (XENE) Stock Forecast & Price Target

$42.45 +0.77 (+1.85%)

(As of 11/26/2024 ET)

Xenon Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 12 Analyst Ratings

Sell
0

Hold
0

Buy
12

Based on 12 Wall Street analysts who have issued ratings for Xenon Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Buy." Out of the 12 analysts, 11 have given a buy rating, and 1 has given a strong buy rating for XENE.

Consensus Price Target

$57.45
35.35% Upside

According to the 12 analysts' twelve-month price targets for Xenon Pharmaceuticals, the average price target is $57.45. The highest price target for XENE is $65.00, while the lowest price target for XENE is $49.00. The average price target represents a forecasted upside of 35.35% from the current price of $42.45.

Get the Latest News and Ratings for XENE and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Xenon Pharmaceuticals and its competitors.

XENE Analyst Ratings Over Time

Type	Current Forecast 11/27/23 to 11/26/24	1 Month Ago 10/28/23 to 10/27/24	3 Months Ago 8/29/23 to 8/28/24	1 Year Ago 11/27/22 to 11/27/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	11 Buy rating(s)	11 Buy rating(s)	9 Buy rating(s)	8 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$57.45	$57.45	$58.78	$52.75
Forecasted Upside	35.35% Upside	37.68% Upside	46.65% Upside	54.60% Upside
Consensus Rating	Buy	Buy	Buy	Buy

Let’s be blunt (Ad)

Let me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)!

Check out the $100 Challenge now

XENE Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

XENE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Xenon Pharmaceuticals Stock vs. The Competition

Type	Xenon Pharmaceuticals	Medical Companies	S&P 500
Consensus Rating Score	3.08	2.80	2.50
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	36.44% Upside	25,330.70% Upside	6.74% Upside
News Sentiment Rating	Neutral News See Recent XENE News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/13/2024	HC Wainwright 2 of 5 stars	D. Tsao Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$53.00 ➝ $53.00	+24.82%
11/13/2024	Needham & Company LLC 3 of 5 stars		Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00	+38.28%
10/10/2024	Raymond James 4 of 5 stars	D. Brill Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$50.00	+26.84%
9/3/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$55.00 ➝ $55.00	+34.44%
8/30/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Minter Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/9/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$65.00 ➝ $65.00	+58.34%
2025 AI Stock Picks: 2 Hidden Gems Under $10/Share (Ad) The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months. 👉[Click here to get your FREE report delivered instantly!]
8/9/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$50.00 ➝ $49.00	+19.63%
5/10/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$62.00 ➝ $60.00	+48.00%
1/2/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$52.00 ➝ $56.00	+23.67%
12/19/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$54.00 ➝ $59.00	+39.38%
12/18/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$53.00 ➝ $62.00	+48.72%
12/8/2023	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$63.00	+61.37%
12/14/2022	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$60.00	+57.60%
12/12/2022	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform
11/28/2022	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight	$50.00	+43.64%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 06:43 PM ET.

XENE Forecast - Frequently Asked Questions

: According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for Xenon Pharmaceuticals is $57.45, with a high forecast of $65.00 and a low forecast of $49.00.
: 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xenon Pharmaceuticals in the last year. There are currently 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" XENE shares.
: According to analysts, Xenon Pharmaceuticals's stock has a predicted upside of 35.35% based on their 12-month stock forecasts.
: Over the previous 90 days, Xenon Pharmaceuticals's stock had 1 upgrade by analysts.
: Xenon Pharmaceuticals has been rated by research analysts at HC Wainwright, Needham & Company LLC, Raymond James, Royal Bank of Canada, and William Blair in the past 90 days.
: Analysts like Xenon Pharmaceuticals more than other "medical" companies. The consensus rating for Xenon Pharmaceuticals is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how XENE compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Crypto’s next big bull run? (Ad)

Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on November 5. Just a day after the American election, Juan believes crypto could start a massive run up …

And one special coin could do even better.

This page (NASDAQ:XENE) was last updated on 11/26/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Xenon Pharmaceuticals (XENE) Stock Forecast & Price Target